PWA
UTHR icon

Principia Wealth Advisory’s United Therapeutics UTHR Stock Holding History

Principia Wealth Advisory’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17K Hold
4
– – ﹤0.01% 566
2026
Q1 		$2.37K Buy
4
+1
+33% +$498 ﹤0.01% 470
2025
Q4 		$1.46K Hold
3
– – ﹤0.01% 553
2025
Q3 		$1.26K Hold
3
– – ﹤0.01% 563
2025
Q2 		$862 Buy
3
+2
+200% +$598 ﹤0.01% 616
2025
Q1 		$293 Sell
1
-1
-50% -$343 ﹤0.01% 705
2024
Q4 		$706 Buy
+2
New +$735 ﹤0.01% 444

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Principia Wealth Advisory's UTHR Position: Q2 2026 in Review

Principia Wealth Advisory held its United Therapeutics (UTHR) position steady in Q2 2026 at 4 shares worth $2.17K. The position accounts for ﹤0.01% of the portfolio, ranked #566.

Principia Wealth Advisory first reported a position in UTHR in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.37K in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Principia Wealth Advisory held 4 shares of United Therapeutics worth $2.17K as of Q2 2026.
  • Principia Wealth Advisory left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Principia Wealth Advisory's portfolio in Q2 2026, its #566 holding.
  • Principia Wealth Advisory first reported a position in United Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Principia Wealth Advisory's United Therapeutics position peaked at $2.37K in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Principia Wealth Advisory's 13F filing for Q2 2026, filed 26 Aug 2026.